2006
DOI: 10.1111/j.1749-4486.2006.01314.x
|View full text |Cite
|
Sign up to set email alerts
|

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non‐typable Haemophilus influenzae: a randomised double‐blind efficacy study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
195
2
27

Year Published

2007
2007
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 478 publications
(231 citation statements)
references
References 0 publications
7
195
2
27
Order By: Relevance
“…§Utilities reported by Prosser et al were used for children aged up to 5 years old. 40 ¶Efficacy against acute otitis media was assumed to be 33.6%, as was shown for the precursor vaccine of PCV-10 by Prymula et al 41 NA, not applicable; PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine; QALY, quality adjusted life year.…”
Section: Cost Effectiveness Of Pcv-10 and Pcv-13mentioning
confidence: 99%
“…§Utilities reported by Prosser et al were used for children aged up to 5 years old. 40 ¶Efficacy against acute otitis media was assumed to be 33.6%, as was shown for the precursor vaccine of PCV-10 by Prymula et al 41 NA, not applicable; PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine; QALY, quality adjusted life year.…”
Section: Cost Effectiveness Of Pcv-10 and Pcv-13mentioning
confidence: 99%
“…This study tested an 11-valent vaccine, not the currently available PCV10. 16 In addition, the POET trial may not be comparable with other studies regarding acute otitis media (AOM). 17,18 Furthermore, it has been shown that PCV10 does not impact carriage for NTHi.…”
Section: Resultsmentioning
confidence: 67%
“…26 Another study on the effects of pneumococcal vaccination on AOM, was the Pneumococcal Otitis Efficacy Trial (POET). 16 Scenario 5 shows the cost-effectiveness when these efficacy numbers were used. Scenarios 6 and 7 explored the effect of the assumed cross-protection of PCV10 against serotype 19A.…”
Section: Epidemiological Datamentioning
confidence: 99%
“…A recent trial showed partial efficacy induced by a conserved surface protein of H. influenzae in preventing otitis media [2]. Both H. influenzae and M. catarrhalis are nonencapsulated Gram-negative bacteria, are exclusively human pathogens, share an ecological niche and cause a similar spectrum of respiratory tract infection.…”
Section: Approach To Vaccine Development For M Catarrhalismentioning
confidence: 99%
“…The role of bacterial infection in triggering otitis media with effusion has yet to be fully elucidated. However, trials that have evaluated vaccines have used acute otitis media exclusively as the end point [1,2]. Future trials of vaccines might include in their design an assessment of the effect of vaccines on otitis media with effusion and chronic otitis media, in addition to acute otitis media.…”
Section: Moraxella Catarrhalis In Otitis Mediamentioning
confidence: 99%